A systematic review of economic evaluations of treatment regimens in multiple myeloma-Reference-Cited by-同舟云学术

A systematic review of economic evaluations of treatment regimens in multiple myeloma

Published:2020-06-27 Issue:4 Volume:21 Page:799-809
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Asrar Mir Mahmood¹^ORCID,Lad Deepesh P.²^ORCID,Prinja Shankar³,Bansal Dipika¹^ORCID

Affiliation:

1. Clinical Research Unit, Department of Pharmacy Practice, National Institute of Pharmaceutical Education & Research, Mohali, Punjab, India

2. Clinical Haematology, Blood & Marrow Transplantation, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

3. School of Public Health, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India

Funder

National Institute of Pharmaceutical Education and Research

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2020.1779064

Reference39 articles.

1. Multiple myeloma

2. Cancer Stat Facts: Myeloma. National cancer institute surveillance, epidemiology, and end results program web site. [cited 2019 Jan 19]. Avilable from: https://seer.cancer.gov/statfacts/html/mulmy.html

3. Global Burden of Multiple Myeloma

4. Improved survival in multiple myeloma and the impact of novel therapies

5. The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Systematic Review of Modeling Approaches to Evaluate Treatments for Relapsed Refractory Multiple Myeloma: Critical Review and Considerations for Future Health Economic Models;PharmacoEconomics;2024-06-25

2. Clinical and economic studies of pharmacotherapy for multiple myeloma: literature review data;South Russian Journal of Therapeutic Practice;2024-06-24

3. Costs of plasmocytic myeloma therapy in the drug programme at a Regional Oncology Centre in Poland;Annals of Agricultural and Environmental Medicine;2023-08-01

4. A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma;Cancers;2021-11-09

5. Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial;PharmacoEconomics;2021-08-09